

Zimbabwe

| High TB burden | High HIV burden |

Tuberculosis profile

Population 2013

14 million

Estimates of TB burden * 2013	Number (thousands)	Rate (per 100 000 population)
Mortality (excludes HIV+TB)	5.7 (3.6–7.4)	40 (25–52)
Mortality (HIV+TB only)	22 (17–27)	153 (121–189)
Prevalence (includes HIV+TB)	58 (33–89)	409 (235–630)
Incidence (includes HIV+TB)	78 (67–91)	552 (474–643)
Incidence (HIV+TB only)	56 (48–66)	395 (341–464)
Case detection, all forms (%)	42 (36–49)	

Estimates of MDR-TB burden * 2013	New	Retreatment
% of TB cases with MDR-TB	1.9 (1–3.3)	8.3 (1.8–23)
MDR-TB cases among notified pulmonary TB cases	520 (270–900)	300 (66–820)

TB case notifications 2013	New **	Relapse
Pulmonary, bacteriologically confirmed	11 404	1 275
Pulmonary, clinically diagnosed	15 807	
Extrapulmonary	4 413	

Total new and relapse	32 899
Previously treated, excluding relapses	2 379
Total cases notified	35 278

Among 32 899 new and relapse cases:
2 567 (8%) cases aged under 15 years; male:female ratio: 1.3

Reported cases of RR-/MDR-TB 2013	New	Retreatment	Total **
Cases tested for RR-/MDR-TB			4 276
Laboratory-confirmed RR-/MDR-TB cases			433
Patients started on MDR-TB treatment			351

TB/HIV 2013	Number	(%)
TB patients with known HIV status	32 460	(92)
HIV-positive TB patients	22 442	(69)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT)	17 267	(77)
HIV-positive TB patients on antiretroviral therapy (ART)	17 267	(77)
HIV-positive people screened for TB	323 431	
HIV-positive people provided with IPT	10 926	

Treatment success rate (%)	(%)
New cases registered in 2012	81
Previously treated cases registered in 2012	
HIV-positive TB cases, all types, registered in 2012	
RR-/MDR-TB cases started on second-line treatment in 2011	81
XDR-TB cases started on second-line treatment in 2011	

Laboratories 2013	
Smear (per 100 000 population)	1.5
Culture (per 5 million population)	0.7
Drug susceptibility testing (per 5 million population)	0.7
Sites performing Xpert MTB/RIF	58


Is second-line drug susceptibility testing available? Yes, in and outside country

Financing TB control 2014	
National TB programme budget (US\$ millions)	31
% Funded domestically	2%
% Funded internationally	43%
% Unfunded	55%

* Ranges represent uncertainty intervals


** Includes cases with unknown previous TB treatment history

(Rate per 100 000 population per year)




Mortality (excludes HIV+TB)

(Rate per 100 000 population)




Prevalence

(Rate per 100 000 population per year)




Notified (new and relapse) Incidence
Incidence (HIV+TB only)

(Number of patients)




HIV-positive TB patients
on CPT on ART

Treatment success rate (%)



New Retreatment
HIV-positive RR-/MDR-TB XDR-TB

Total budget (US\$ millions)



Funded domestically Funded internationally
Unfunded